Developing a Method to Quantify Swelling Force Generated by the Osmotic Pump Tablet Push Layer †
Abstract
1. Introduction
2. Materials and Methods
3. Results
3.1. Drug Release
3.2. Configuration Setup
3.3. Swelling Force
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
| API | Active pharmaceutical ingredient |
| AUCFs,0–15h | Area under swelling-force curve from 0 to 15 h |
| AUCFs,0–24h | Area under swelling-force curve from 0 to 24 h |
| Fs15 h | Swelling force at 15 h |
| Fs24 h | Swelling force at 24 h |
| Fs,max | Maximum swelling force |
| Fe2O3 | Iron oxide |
| FFBE | Flat-face beveled-edge |
| g | Gram |
| h | Hours |
| HPLC | High-performance liquid chromatography |
| HSD | Honestly significant difference |
| kg | Kilogram |
| mL | Milliliter |
| mm | Millimeter |
| MW | Molecular weight |
| n | Number of repetitions |
| NaCl | Sodium Chloride |
| OSDF | Oral solid dosage form |
| PEO | Polyethylene oxide |
| PPOP | Push–Pull osmotic pump |
| UV | Ultraviolet |
References
- Almoshari, Y. Osmotic pump drug delivery systems—A comprehensive review. Pharmaceuticals 2022, 15, 1430. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Gao, H.; Wang, C.; Chen, F. Effects of Geometric Characteristics of Tablet on the Performance of Push-Pull Osmotic Pump Drug Delivery System. Chin. Pharm. J. 2021, 56, 1927–1931. (In Chinese) [Google Scholar] [CrossRef]
- Conley, R.; Gupta, S.K.; Sathyan, G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr. Med. Res. Opin. 2006, 22, 1879–1892. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Pfizer Inc. Procardia XL (Nifedipine) Extended-Release Tablet, Film Coated [Prescribing Information]. DailyMed. U.S. National Library of Medicine, 27 November 2023. Available online: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ebcb33c-f43b-4b36-9f94-9774b2a59e06 (accessed on 23 October 2025).
- Sun, Y.; Zhang, Y.; Liu, F.; Liu, X.; Hidru, T.; Yang, X.; Jiang, Y. The relationship between circadian rhythm of blood pressure and vascular dysfunction in essential hypertension. Clin. Exp. Hypertens. 2023, 45, 2229535. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Venkateswarlu, B.; Pasupathi, C.; Pasupathi, A.; Jaykar, B.; Chandira, R.; Palanisamy, P. Osmotic drug delivery system: A review. J. Drug Deliv. Ther. 2019, 9, 759–764. [Google Scholar] [CrossRef] [Scilit]
- Pophalkar, P.; Karole, S. Development of osmotic drug delivery system to control the release pattern of drug repaglinide. Int. J. Res. Pharm. Sci. 2023, 14, 116–127. [Google Scholar] [CrossRef] [Scilit]
- Tomar, B.S.; Tirumkudulu, M.S.; Yu, W.; Berchielli, A.; Doshi, P. Osmotic tablet coatings: Drying stress, mechanical properties and microstructure. Int. J. Pharm. 2022, 617, 121611. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Brunner, A.; Mader, K.; Gopferich, A. pH and osmotic pressure inside biodegradable microspheres during erosion. Pharm. Res. 1999, 16, 847–853. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhao, X.; Li, Q.; Gong, X.; Li, S. The delivery mechanism of micro-porous osmotic pump tablets. Acta Pharm. Sin. 2007, 42, 226–230. (In Chinese) [Google Scholar] [CrossRef]
- Wang, W.; Xie, X.; Yang, D.; Chen, X. A preliminary study on the properties of commonly used hydrophilic expandable materials and their application in push-pull osmotic pump tablets. Chin. J. Tradit. Chin. Med. 2009, 34, 2319–2321. (In Chinese) [Google Scholar] [CrossRef] [PubMed]
- Liu, L.; Zhang, K.; Sun, Z.; Dong, Q.; Li, L.; Zang, H. A new perspective in understanding the dissolution behavior of nifedipine controlled release tablets by NIR spectroscopy with aquaphotomics. J. Mol. Struct. 2021, 1230, 129872. [Google Scholar] [CrossRef] [Scilit]
- Chen, F.; Wang, C.; Gao, H. Key formulation considerations of push-pull osmotic pump (PPOP) drug delivery system. Chin. Pharm. J. 2019, 54, 783–789. [Google Scholar] [CrossRef]
- Yin, X.; Li, H.; Liu, R.; Chen, J.; Ji, J.; Chen, J.; Shao, Q.; Xiao, T.; York, P.; He, Y.; et al. Fractal structure determines controlled release kinetics of monolithic osmotic pump tablets. J. Pharm. Pharmacol. 2013, 65, 953–959. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Deng, L.; Fu, Y. Seeing is believing: Time-lapse macro-imaging of morphological changes of solid dosages as a teaching and research tool. Pharm. Res. 2022, 39, 1019–1024. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Le Neel, T.; Morlet-Renaud, C.; Lipart, C.; Gouyette, A.; Truchaud, A.; Merle, C. Image analysis as a new technique for the study of water uptake in tablets. S.T.P. Pharma Sci. 1997, 7, 117–122. [Google Scholar]
- Malaterre, V.; Metz, H.; Ogorka, J.; Gurny, R.; Loggia, N.; Maeder, K. Benchtop-magnetic resonance imaging (BT-MRI) characterization of push-pull osmotic controlled release systems. J. Control. Release 2009, 133, 31–36. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lin, W.; Li, Y.; Shi, Q.; Liao, X.; Zeng, Y.; Tian, W.; Xie, X.; Liu, H. Preparation and evaluation of bilayer-core osmotic pump tablets containing topiramate. PLoS ONE 2022, 17, e0264457. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Upadhye, S.; Rajabi-Siahboomi, A. Properties and applications of polyethylene oxide and ethylcellulose for tamper resistance and controlled drug delivery. In Melt Extrusion, AAPS Advances in the Pharmaceutical Sciences Series; Springer: New York, NY, USA, 2013; Volume 9, pp. 145–158. [Google Scholar] [CrossRef] [Scilit]
- Robart, S.; Rogers, T.L.; Watson, T.; Putans, B.; Bernthal, H. Quantitating Swelling Pressure Generated by the Push Layer of an Osmotic Pump Tablet. In Proceedings of the AAPS PharmSci360 Annual Meeting and Exposition, San Antonio, TX, USA, 9–12 November 2025. [Google Scholar]
- Rogers, T.L.; Horton, A.J.; Watson, T.; Robart, S.; DeFrancesco, B.; Bishop, H.; Tocce, E. Oral Tablet Formulations with Lactoferrin, a Cohesive Biomacromolecule. Pharmaceutics 2025, 17, 1151. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Knarr, M. Advanced analysis of alginate for treatment of gastresophageal reflux disease. Gastroenterol. Hepatol. Open Access 2025, 16, 46–49. [Google Scholar] [CrossRef] [Scilit]












| Product | Active Pharmaceutical Ingredient | Company | Treatment Type |
|---|---|---|---|
| Procardia XL | Nifedipine | Pfizer/ALZA | Antihypertensive |
| Adalat CC | Nifedipine | Bayer | Antihypertensive |
| Glucotrol XL | Glipizide | Pfizer/ALZA | Antidiabetic |
| Ditropan XL | Oxybutynin | ALZA | Overactive bladder |
| Concerta | Methylphenidate | Janssen/ALZA | Attention-Deficit Hyperactive Disorder |
| Invega | Paliperidone | Janssen | Antipsychotic |
| Cardura XL | Doxazosin | Pfizer | Benign Prostatic Hypertrophy/Antihypertensive |
| Covera-HS | Verapamil | Searle/ALZA | Antihypertensive |
| Jurnista/Exalgo | Hydromorphone | ALZA/Janssen | Pain management |
| Material | Brand Name (If Applicable) | Lot Number | Supplier |
|---|---|---|---|
| PEO 100,000 i | POLYOX™ WSR N10 | 2744225711 | Roquette(Institute, WV USA) |
| PEO 200,000 i | POLYOX™ WSR N80 | 2744703171 | Roquette (Institute, WV USA) |
| PEO 1,000,000 i | POLYOX™ WSR N-12K | 2744209048 | Roquette (Institute, WV USA) |
| PEO 2,000,000 i | POLYOX™ WSR N-60K | D682L8VPM5 | Roquette (Institute, WV USA) |
| PEO 4,000,000 i | POLYOX™ WSR 301 | 2744613478 | Roquette (Institute, WV USA) |
| PEO 5,000,000 i | POLYOX™ WSR Coagulant | 2744659049 | Roquette (Institute, WV USA) |
| PEO 7,000,000 i | POLYOX™ WSR 303 | 2744666856 | Roquette (Institute, WV USA) |
| Micronized NaCl ii | Micro 95 1.5% TCP iii | 0041399972 | Cargill (Akron, OH USA) |
| Red Fe2O3 iv | P28K015 | Thermo Scientific (Allentown, PA USA) |
| PEO MW Grade i in Push Layer | Fs15h ii | Fs24h iii | Fs,max iv | AUCFs,0–15h v | AUCFs,0–24h vi |
|---|---|---|---|---|---|
| PEO 100,000 | 134 ± 95 | 3 ± 1 | 464 ± 24 | 4811 ± 489 | 5036 ± 693 |
| PEO 200,000 | 233 ± 148 | 5 ± 2 | 956 ± 164 | 9566 ± 1620 | 10,059 ± 1705 |
| PEO 1,000,000 | 808 ± 174 | 204 ± 111 | 1563 ± 184 | 17,794 ± 1993 | 22,037 ± 3074 |
| PEO 2,000,000 | 943 ± 243 | 315 ± 167 | 1743 ± 213 | 20,153 ± 2957 | 25,464 ± 4589 |
| PEO 4,000,000 | 1279 ± 209 | 548 ± 221 | 2058 ± 116 | 24,332 ± 1827 | 32,368 ± 3838 |
| PEO 5,000,000 | 1263 ± 336 | 652 ± 220 | 1943 ± 277 | 23,569 ± 4262 | 32,171 ± 7003 |
| PEO 7,000,000 | 1235 ± 194 | 699 ± 121 | 1764 ± 223 | 22,075 ± 2683 | 30,719 ± 4063 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Rogers, T.L.; Robart, S.; Watson, T.; Wang, R.; Bernthal, H.; Ahmadi, V. Developing a Method to Quantify Swelling Force Generated by the Osmotic Pump Tablet Push Layer. Pharmaceutics 2026, 18, 1174. https://doi.org/10.3390/pharmaceutics18091174
Rogers TL, Robart S, Watson T, Wang R, Bernthal H, Ahmadi V. Developing a Method to Quantify Swelling Force Generated by the Osmotic Pump Tablet Push Layer. Pharmaceutics. 2026; 18(9):1174. https://doi.org/10.3390/pharmaceutics18091174
Chicago/Turabian StyleRogers, True L., Stephanie Robart, Thomas Watson, Rhea Wang, Harold Bernthal, and Vahid Ahmadi. 2026. "Developing a Method to Quantify Swelling Force Generated by the Osmotic Pump Tablet Push Layer" Pharmaceutics 18, no. 9: 1174. https://doi.org/10.3390/pharmaceutics18091174
APA StyleRogers, T. L., Robart, S., Watson, T., Wang, R., Bernthal, H., & Ahmadi, V. (2026). Developing a Method to Quantify Swelling Force Generated by the Osmotic Pump Tablet Push Layer. Pharmaceutics, 18(9), 1174. https://doi.org/10.3390/pharmaceutics18091174

